Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2016

View Archived Issues

Shire reports milestones of first quarter 2016

AstraZeneca reports results of first quarter 2016

Concert Pharmaceuticals developing CTP-543 for alopecia areata

NicOx's NO-donating travoprost derivative in models of ocular hypertension

CLG-561 for AMD

Anti-c-Met antibody-drug conjugate from Sorrento to enter IND-enabling studies

TEASE: early phase II data for ALK-001

First clinical results for CFI-400945 show signs of activity in patients with solid tumors

WAVE Life Sciences and Pfizer agreement for development of optimized therapeutics

Audentes Therapeutics forms partnerships to advance AAV therapy for Crigler-Najjar syndrome

Seres Therapeutics enters agreements fro microbiome therapeutics for IBD

Wellcome Trust award to advance development of Kineta's Lassa fever treatment

Opthea gives update on phase IIa dose-expansion study of OPT-302 in wet AMD

New results from Conatus' phase II study of emricasan in liver cirrhosis

NS4B inhibitor YF-01 demonstrates efficacy in a hamster model of YFV infection

Combination cancer vaccine CMB-305 named FDA orphan treatment for soft tissue sarcoma

Shenzhen University patents piscidin analogues

Bristol-Myers Squibb discloses PD-1/CD80 interaction inhibitors

Novo Nordisk reports GLP-1 analogues

Merck & Co. presents HIF prolyl hydroxylase inhibitors

Redx Pharma introduces Wnt signaling and PORCN inhibitors

Ligand acquires rights to several programs from medical device company

Novel FASN inhibitors demonstrate efficacy in NSCLC and CRC models

Merus announces dosing of first patient in phase I/II trial of MCLA-117 in patients with AML

Medivation reiterates rejection of Sanofi proposal

FDA advisory committee votes on KemPharm's Apadaz

NIH grant supports Scripps' development of RNA-based therapeutics

Phase III trials of tildrakizumab in moderate to severe plaque psoriasis meet primary endpoints

Sirnaomics obtains funding to support fibrosis programs

Clovis terminates rociletinib studies, withdraws MAA, according to Q1 2016 overview